Sanofi's CEO on AI in pharma; ALS advocates on criticism of new drugs

Taking stock of the drug industry, from the lab to the medicine chest

September 8, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe Opinion: Sanofi CEO Paul Hudson: The right way to bring AI into pharma Sanofi CEO Paul Hudson on the potential for AI to drive insights and better decision intelligence in the pharmaceutical industry. By Paul Hudson STAT+ | Why Novartis is changing the name of its research labs The new name reflects a shift from research being driven by the pursuit of scientific discovery to a tighter focus on commercial success. By Jonathan Wosen STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman STAT ALS advocates say criticism of new drugs misses bigger picture Brian Wallach and Sandra Abrevaya prepare for an FDA decision on another controversial drug candidate for ALS. By Lev Facher

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser